Skip to main content
Consun Pharmaceutical Group Limited logo

Consun Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1681 HKEX Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2025-07-15 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1681

About Consun Pharmaceutical Group Limited

http://www.chinaconsun.com

Consun Pharmaceutical Group Limited is a modern pharmaceutical enterprise engaged in the integrated research, development, manufacturing, and marketing of pharmaceutical products. The company's core business is segmented into Modern Chinese Medicines (MCM) and Medical Contrast Medium products. The MCM portfolio targets major therapeutic areas, including chronic renal diseases (featuring products like Uremic Clearance Granules), liver and gallbladder conditions, and orthopedic trauma. In the medical imaging field, Consun supplies contrast agents such as Gadopentetate Dimeglumine Injection for magnetic resonance imaging (MRI) and Iopamidol Injection for angiography and neuro-radiology. The enterprise focuses on combining the modernization of Chinese medicine with advanced diagnostic solutions.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a ‘Next Day Disclosure Return’ filed under HKEX Main Board/GEM listing rules (Rule 13.25A/17.27A, 10.06(4)(a), etc.) detailing changes in issued shares and multiple on-market share repurchases, including volumes, dates, prices and confirmations. This is a statutory trading return specifically reporting the company’s own share buybacks/treasury sales. It matches the definition of ‘Transaction in Own Shares’ (Code: POS).
2025-07-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares (option exercises), share repurchases for cancellation (Sections I and II) and on-market sale of treasury shares (Section III). It is a regulatory disclosure of the company’s own share transactions (buy-backs, cancellations, treasury sales), not an earnings, management or strategy report. This matches the definition of “Transaction in Own Shares” (POS).
2025-07-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return filed under Hong Kong Stock Exchange rules detailing changes in issued shares (due to option exercises) and extensive repurchases of treasury shares on-market. It provides specific transaction dates, quantities, prices, and confirmations by the company secretary. This clearly falls under the category of a company’s own share transactions (buybacks and treasury share dealings), corresponding to Transaction in Own Shares (POS).
2025-07-11 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) required under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares (via option exercises) and share repurchases (on-market buybacks and treasury share sales). This is a mandatory report of the company’s own share transactions. It falls under the “Transaction in Own Shares” category (POS).
2025-07-10 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a "Next Day Disclosure Return" (Form FF305) under Hong Kong Stock Exchange Listing Rules, detailing changes in issued shares and treasury shares, specifically multiple share repurchases and the repurchase mandate. This is not an annual or interim report, nor a board change announcement, but a regulatory disclosure of transactions in the company’s own shares (share buybacks). Therefore, it falls under Transaction in Own Shares (POS).
2025-07-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return filed under the Hong Kong Listing Rules, detailing changes in issued shares and treasury shares (Sections I–III) and reporting on share repurchases on-market (Section II) as required under Main Board Rule 10.06 and GEM Rule 13.13. It constitutes a report of the company’s own share transactions (buybacks and treasury share sales). Thus, it falls squarely under ‘Transaction in Own Shares’ (POS).
2025-07-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.